Skip to content
Research Article Open access CC BY 4.0

Outlook on Genetically Engineered CAR T-Cell Therapies for Solid Tumours

Yana Pautova, Yuri Tolkunov, Luis Mendoza, Brian Churchill

International Research Journal of Oncology · pp. 207–211 · Published 29 Jul 2021

Abstract

T-cell-based methods using genetic engineering technology are considered the most advanced treatments in cancer therapy. Chimeric antigen receptor (CAR) T-cell therapy is an innovative immunotherapy wherein autologous T-cells are genetically modified to recognize and destroy cancer cells more effectively. CAR T-cell therapy has shown remarkable success in the treatment of CD19-expressing hematologic malignancies. However, such extraordinary experience has not been translated to treatment of solid tumors, where its efficacy remains limited. This article gives an overview of these obstacles that CAR T-cells research needs to overcome to achieve efficient next-generation T-cell therapy for solid malignancies.

CAR T-cell therapy solid tumours clinical trials T-cells

Cited by 0

No indexed citations yet.

Article metrics

Real usage data collected on this platform.

0

Page views

0

PDF downloads

0

Outbound clicks

0

Citations

Views by country

Approximate, from request IP at view time — not citizenship or institution. Countries with fewer than 5 views are grouped as "Other".

No views recorded yet.

Traffic sources

Referring site, by host.

No traffic recorded yet.

Views and downloads exclude known bots/crawlers. Citations combines this platform's own DOI-resolved index with each external source's own reported total — see Cited by above for individually listed citing works. Last refreshed 0 seconds ago.